BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

2020-02-26T16:12:06+00:00

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics Licens [...]

BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 20202020-02-26T16:12:06+00:00